The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
 
Thatcher Ross Heumann
Honoraria - Total Health
Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Primum
Travel, Accommodations, Expenses - Eisai
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Judy Murray
No Relationships to Disclose
 
Jiayun Lu
No Relationships to Disclose
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst)
 
Paul Raymond Kunk
Consulting or Advisory Role - Exelixis
Research Funding - Array BioPharma; Exelixis
 
Renuka V. Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bayer; Eisai; Exelixis; Incyte; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sandoz; Sun pharma; Tersera
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - AstraZeneca; Genentech; Replimune
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis
Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Lionel Aurelien Kankeu Fonkoua
Honoraria - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - AstraZeneca; Boston Scientific; BTG; Elevar Therapeutics; Exelixis; Genentech; Incyte
Speakers' Bureau - AstraZeneca; Boston Scientific; Exelixis; Genentech/Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Olumide B. Gbolahan
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; Incyte; Merck Sharp & Dohme; QED Therapeutics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Eisai (Inst); Pfizer (Inst); Zymeworks (Inst)
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Vaia Florou
Consulting or Advisory Role - Deciphera; Incyte
 
John J. Wright
No Relationships to Disclose
 
Elad Sharon
Consulting or Advisory Role - D.E. Shaw Research; Mallinckrodt/Therakos
 
Hao Wang
No Relationships to Disclose
 
Gregory B. Lesinski
Research Funding - Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst); Novartis (Inst); Vaccinex (Inst)
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology; Irazu; Tempus
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics